Naproxen in rheumatoid arthritis

Extended trial

A. G. MOWAT,* B. M. ANSELL,† J. M. GUMPEL,‡ H. F. H. HILL,§ A. G. S. HILL, § AND M. STOPPARD**

From the Rheumatology Unit, Nuffield Orthopaedic Centre, Oxford;* Canadian Red Cross Memorial Hospital, Taplow;† Northwick Park Hospital, Harrow;‡ Rheumatism Research Centre, Stoke Mandeville Hospital;§ and Syntex Pharmaceuticals, Maidenhead**

Naproxen (d-2(6'-methoxy-2'-napthyl)-proprionic acid) was introduced into clinical practice in the United Kingdom in September 1973. In a standard, double-blind, 8-week cross-over study comparing naproxen 500 mg/day with aspirin 4 g/day in patients with rheumatoid arthritis the two drugs were found to be equally effective in controlling this disease as assessed by objective and subjective parameters (Hill and others, 1973, 1974). Naproxen was better tolerated, and in particular, was associated with less dyspepsia or evidence of gastrointestinal bleeding. Since such side effects are a major problem in the treatment of rheumatoid arthritis, this paper describes the use of naproxen for a mean of 10 months in 121 patients with rheumatoid arthritis, the majority of whom has proved intolerant of other nonsteroidal, anti-inflammatory (NSA) agents.

Patients

The 121 patients, 96 women and 25 men, from four centres, consisted of three groups. (i) 16 patients who after initial cross-over studies with aspirin agreed to take part in a longer trial. (ii) 91 patients who had proved intolerant of one or more standard NSA agents sufficient to cause their discontinuation. (iii) 14 patients who had experienced inadequate symptomatic relief from other NSA agents.

The mean age of the patients was 56-6 years (range 26-80 years). The mean duration of disease was 10-1 years (range 6 months–38 years). All were outpatients with active, classical or definite rheumatoid arthritis. Those in groups (ii) and (iii) exhibited three of the following symptoms: 4 or more tender or painful joints, 4 or more joints with active synovitis, morning stiffness of more than 45 minutes' duration, and an erythrocyte sedimentation rate (Westergren) 28 mm/1 h. However, most patients in group (i), although they had fulfilled these clinical criteria on admission to the 8-week cross-over study with naproxen 500 mg/day and aspirin 4 g/day now had less active disease. All three groups were similar with respect to sex, age, and duration of disease.

Method

In general patients were assessed at 1, 3, 6, and 12 months and thereafter at 6-monthly intervals, with additional assessments on withdrawal from the study. Assessment was by the same observer at each centre, who used the same routine clinical measurements as in the initial cross-over studies with aspirin (Hill and others, 1974). The following were measured and recorded: functional...
class (graded 1–4); duration of morning stiffness (graded 0–7); severity of pain at rest and on movement (graded 0–2); the number of painful joints during a full range of active, nonweight-bearing motion (0–16); the number of tender and/or swollen proximal interphalangeal joints (0–8); total proximal interphalangeal joint circumference for each hand; grip strength in both hands; and walking time for a distance of 50 feet.

The patient and physician also made five point, graded overall assessments of the severity of the current disease and of the change from the last visit. Routine biochemical, haematological, and urine tests were undertaken at each visit.

The patients were not asked specifically about possible listed side effects but were merely asked whether they had any problems or difficulties with the drug. Any complaint was discussed with the patient, and if it appeared to be drug related the association was classified as being definite or possible (Hill and others, 1974; Huskisson and Wojtulewski, 1974).

Naproxen 250 mg was given twice daily, although an increase in dosage was permitted, while concomitant therapy with gold, corticosteroids, or antimalarials was continued unchanged throughout the study.

Results

CLINICAL

The mean treatment time (±1SD) was 10.41 months ±8.81, with one patient completing 32 months of treatment. Clinical measurements have been compared with baseline values for each of the standard intervals up to 24 months, small numbers of patients making subsequent calculations invalid.

There were no significant differences in the results between any patient group. There were significant and maintained improvements in morning stiffness, the number of painful joints, the number of tender and/or swollen proximal interphalangeal joints, the mean proximal interphalangeal joint circumference for each hand, grip strength, and walking time (Table I). There were no changes in functional capacity while patients only showed a significant reduction over baseline values in pain at rest up to 6 months (P<0.05) and in pain on movement up to 12 months (P<0.001). As would be expected from the above, both patients and physicians recorded modest overall improvement at each assessment.

LABORATORY

No abnormal biochemical or urine results were recorded, nor were there significant changes in the ESR or haemoglobin values. In particular, there were no significant changes in the haemoglobin values in the patients in group (ii), those who had a past history of side effects, frequently indigestion, to other standard NSA agents.

SIDE EFFECTS

The number of patients complaining spontaneously of side effects and whether or not after discussion

<table>
<thead>
<tr>
<th>Table II Side effects in groups i, ii, iii</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Side effect</strong></td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Indigestion</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Diarrhoea/</td>
</tr>
<tr>
<td>constipation</td>
</tr>
<tr>
<td>Anoxia</td>
</tr>
<tr>
<td>Malaena</td>
</tr>
<tr>
<td>Tinnitus</td>
</tr>
<tr>
<td>Sleeplessness</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td>Rash</td>
</tr>
<tr>
<td>Sore mouth</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Total (%)</td>
</tr>
<tr>
<td>(of patients)</td>
</tr>
</tbody>
</table>

Figures in parentheses are the number of patients remaining in the trial.

All measures are significant at least P<0.05 (Student's t-test).

PIP = proximal interphalangeal joints.
between the patient and physician the effect was considered to be due to the drug are given in Table II. As expected, a higher percentage of patients from group (ii) with a past history of side effects had side effects to naproxen.

**PATIENT WITHDRAWALS**

Naproxen was withdrawn usually because of side effects or lack of clinical benefit in 46 patients (Table III). 38 of these were in group (ii), with 4 patients being withdrawn from both groups (i) and (iii). As expected all the withdrawals from group (iii) were because the patients found naproxen, like the other NSA agents they had tried, ineffective. Almost half the withdrawals from group (ii) were due to side effects.

Overall, 22 patients (18.2%) were withdrawn because of lack of clinical benefit, 19 (15.7%) because of side effects, and 5 (4.1%) for other reasons, including unrelated death due to cervical carcinoma, and rheumatoid vasculitis, disease in remission (2 cases), and a wish to try a different drug after 26 months of treatment.

**Table III** Withdrawals from trial

<table>
<thead>
<tr>
<th>Reason for withdrawal</th>
<th>Group i (n=16)</th>
<th>Group ii (n=91)</th>
<th>Group iii (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ineffective</td>
<td>2</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>Side effects</td>
<td>1</td>
<td>18</td>
<td>—</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>4</td>
<td>—</td>
</tr>
</tbody>
</table>

**DRUG DOSAGE AND REGIMENS**

Naproxen was started in an initial dose of 250 mg twice daily, and although changes were permitted to improve the clinical response, 96 patients were maintained on this regimen. In a further 10 patients the twice-daily regimen was maintained but the total daily dose was increased to 750 mg, the majority of patients preferring 500 mg in the evening. Dosage was reduced to 125 mg twice daily in one patient, while the remainder received 250 mg three times per day. These final drug dosages represent a range of from 4 to 19 mg naproxen/kg body weight per day (mean 9.4).

**Discussion**

A number of chemically similar nonsteroid anti-inflammatory agents have been introduced into clinical practice in the United Kingdom during the past 3 years and new products will appear shortly. The requirements of the Committee for the Safety of Medicines and the Pharmaceutical Companies Marketing Departments ensure that all such drugs will have been shown to be clinically effective, to be comparable in effect in short-term trials to full doses of aspirin, and to have few side effects. Such studies will also have indicated an average optimum daily dose of the new drug. Almost all patients with rheumatoid arthritis, however well their disease is controlled, show some clinical improvement during short-term clinical trials with active drugs, suggesting that frequent assessment and encouragement in hospital clinics and supervision of drug taking are both beneficial. Thus, such studies do not necessarily indicate the possible effect of the drug in extended clinical usage. Further, short-term studies may also fail to show the true incidence of side effects to the new drug. Lastly, since most of these drugs are introduced into clinical practice with a suggested optimum (and frequently fixed) dosage which takes no account of differences in body weight and of differences in the patient's absorption, metabolism, and excretion of the drug, many patients may experience minimal or a declining clinical benefit if the chosen dose is too small.

This extended follow-up of naproxen in patients with rheumatoid arthritis was undertaken to assess whether the initial standard drug dosage and regimen needed to be adjusted and whether the drug continued to show clinical benefit with a low incidence of side effects over a period of months with only occasional hospital assessment. Only patients with active disease were included in the study while a high proportion of the patients were either intolerant of or had found ineffective the commonly used drugs such as aspirin preparations and indomethacin. This selection of patients was deliberate since it is chiefly in these 'difficult to treat' patients that a change from the commonly used drugs is indicated. The treatment of mild cases who have shown good tolerance to existing drugs is likely to show encouraging but unhelpful results.

On the basis of a number of standard objective and subjective parameters the study shows that the clinical benefit of naproxen in patients with rheumatoid arthritis, shown in an initial double-blind study (Hill and others, 1974), continues for up to 32 months. Naproxen has a clear analgesic effect and on the basis of the duration of morning stiffness, the number of swollen and tender proximal interphalangeal joints, grip strength, and changes in proximal interphalangeal joint circumference, probably the best test (Boardman and Hart, 1967), sustained anti-inflammatory activity.

All patients were started on the recommended dose of 250 mg naproxen twice daily, changes in dosage and regimen being required in only 25 patients. Dosage ranged from 4 to 19 mg/kg body weight per day on this regimen, thus indicating that tailoring the dosage on the basis of body weight...
is not useful. A thrice-daily regimen was rarely necessary, confirming the 12-hour duration of action of the drug.

Forty-six of the 121 patients had to be withdrawn from the trial, although 5 withdrawals were for reasons unconnected with the drug therapy. 21 patients were withdrawn, the majority within the first 3 months of the study, because of lack of clinical benefit. All 4 withdrawals from group (iii) were because the patients found naproxen, like other NSA agents they had tried, ineffective. However, 16 of 91 patients (17.5%) from group (ii) found the drug ineffective and required other treatment, often gold, penicillamine, or an increase in corticosteroid dosage. 19 patients were withdrawn, again mostly within the first 3 months of the study, because of side effects. All but one of these were from group (ii), those patients intolerant of other NSA agents. The good tolerance of naproxen confirms the findings of earlier trials and its withdrawal from only 19.8% of this difficult group of patients is considered satisfactory. As with most current trials of NSA agents patients were not asked to choose from a specific list of possible side effects but were simply asked, 'have you had any problems or difficulties with the drug?' (Huskisson and Wojtulewski, 1974). 28 complained of a range of side effects chiefly related to the gastrointestinal and central nervous systems, which were considered by both patients and physician to be due to naproxen, while a further 50 patients complained of a similar range of side effects not considered to be directly attributable to the drug. In neither instance was the usual high incidence of nausea and dyspepsia, recorded with other NSA agents, noted. Further, there were no proved instances of a naproxen-induced rash. The incidence of these side effects confirms the findings of the earlier, short-term trials (Hill and others, 1974) and shows that extended treatment with naproxen is not associated with a higher or increasing incidence of side effects.

Finally, despite occasional reports of severe gastrointestinal tract bleeding with naproxen (Hart, 1974; Matts, 1974), there is no evidence in this study from sequential haemoglobin values and a single report of malaena that this is a common side effect. Clearly the drug does cause some gastrointestinal tract blood loss (Hill and others, 1974; Halvorsen, Dotevall, and Sevelius, 1973), and with any widely used preparation there will inevitably be a small number of patients who have more serious, idiosyncratic bleeding episodes (Mowat, 1973). Other routine, haematological, biochemical, and urine testing did not show any abnormalities.

References


Naproxen in rheumatoid arthritis. Extended trial.

A G Mowat, B M Ansell, J M Gumpel, H F Hill, A G Hill and M Stoppard

doi: 10.1136/ard.35.6.498

Updated information and services can be found at:
http://ard.bmj.com/content/35/6/498

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/